MINNEAPOLIS, April 28 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that it will release financial results for the first quarter ended March 29, 2008 after the market close on Monday, May 5, 2008. The Company will host a conference call and webcast on Monday, May 5, 2008 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the Company's first quarter results and current corporate developments. The dial-in number for the conference call is 800-218-4007 for domestic participants and 303-262-2142 for international participants.
A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 800-405-2236 for domestic participants and 303-590-3000 for international participants, using the passcode 11112192#. A live webcast of the call can be accessed at http://www.atsmedical.com by clicking on the Investors icon. The webcast will also be archived on the company's website.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
|SOURCE ATS Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved